Illumen Therapeutics Inc.
The University of Colorado Connection
Illumen Therapeutics is pursuing a cancer treatment moonshot, developing PARN Inhibitor drugs to increase functional p53, the 'Guardian of the Genome,' to treat aggressive cancers. Dysregulation of p53, a tumor suppressor protein, is the hallmark of nearly all cancers. Drugging p53 has been considered the Holy Grail of cancer drug development. The company is the first to pursue this novel, promising therapeutic strategy of inhibiting PARN to increase functional p53 to treat wild-type p53 aggressive cancers. PARN as a target and the therapeutic strategy of inhibiting PARN to increase functional p53 was discovered by Roy Parker (CU Boulder Biochemistry, BioFrontiers Institute).
Funding Status and Investment Opportunities
- Industry: Biotech, Therapeutics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: Bob Blomquist , CEO, bob@IllumenTx.com
In the News
Venture Partners Programs
This technology was developed with funding from
U.S. National Institutes of Health (NIH), Howard Hughes Medical Institute
This page was last updated on April 4, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.